Gregory Fraser
Stock Analyst at Truist Securities
(3.25)
# 1,008
Out of 4,876 analysts
36
Total ratings
51.85%
Success rate
14.82%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Hold | $62 → $65 | $65.90 | -1.37% | 9 | Apr 21, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $220 → $230 | $107.59 | +113.77% | 1 | Mar 6, 2025 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $6.41 | +9.20% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $0.16 | +4,798.96% | 6 | Apr 30, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $4.28 | +110.28% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $8.13 | -13.90% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $74.33 | -60.98% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $17.10 | +455.56% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $9.31 | +93.34% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $14.40 | +177.78% | 2 | May 26, 2023 |
ANI Pharmaceuticals
Apr 21, 2025
Maintains: Hold
Price Target: $62 → $65
Current: $65.90
Upside: -1.37%
Jazz Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $107.59
Upside: +113.77%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $6.41
Upside: +9.20%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.16
Upside: +4,798.96%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $4.28
Upside: +110.28%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $8.13
Upside: -13.90%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $74.33
Upside: -60.98%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $17.10
Upside: +455.56%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $9.31
Upside: +93.34%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $14.40
Upside: +177.78%